Geriatric oncologists have two main challenges: (I) selecting patients for specific treatments and (II) the delicate balance of prolonging their survival, whilst maintaining independence and quality of life. Since elderly patients are underrepresented in cancer clinical trials, it is hard to have evidence-based recommendations in everyday clinical practice. The Group conducts elderly-specific clinical research to meet these two challenges.


  • Cancer in Elderly Group

    EORTC elderly task force position paper: Approach to the older cancer patient.

    As life expectancy increases and the population ages, the number of cancer cases diagnosed in individuals over the age of 65 has grown. In response to this, the EORTC established the Elderly Task Force (ETF) in 1992 to dedicate a group on this growing problem and investigate differences in malignant behavior, treatment, and quality of life in older patients versus younger. In 2010, the EORTC released a position paper outlining the influence of age on cancer presentation and cancer management in older cancer patients, to suggest changes in clinical trial methodology.

  • Cancer in Elderly Group

    EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors.

    The EORTC and its Elderly Task Force organized a workshop on clinical trial methodology in older cancer patients. They concluded that clinical trials investigating elderly patients, should add quality of life, functional status, and independence as end points (outcome measures), all of which comprise key issues raised by this age group. In addition, the panel released recommendations for designing and reporting clinical trials in the elderly population and established a data set to evaluate global health status for this age group.

  • Leukemia Group / Elderly

    EORTC 06012 – Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 – 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC – LG and the GIMEMA-ALWP.

    EORTC found that the addition of gentuzumab ozogamicin (GO) prior to standard induction treatment provides no benefit for patients of 61 to 75 years old with acute myelogenous leukemia (AML).


  • Leukemia Group / Elderly

    EORTC 06011 – Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10% blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for intensive therapy.

    An EORTC-German MDS Study Group randomized phase III study.

    This EORTC study established the efficacy and safety of treatment with decitabine, in elderly patients with higher-risk Myelodysplastic Syndrome (MDS).


  • Mar-10
  • Aug-11
  • Oct-13
  • Dec-15


Want to read in detail our scientific findings on specific tumour type?
Search through our comprehensive list of EORTC published articles to date.

Search for an article
Sign up